Organization
Morinomiya University of Medical Sciences, Graduate School of Health Science, Osaka, Japan
1 abstract
Abstract
BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIESOrg: Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet Herne, Bochum, Germany, Oregon Health & Science University, Arthritis and Rheumatic Diseases, Portland, United States of America, Leiden University Medical Center (LUMC), Department of Rheumatology, Leiden, Netherlands, University Hospitals, Case Western Reserve University, Cleveland, United States of America, University of Alberta, Department of Medicine, Edmonton, Canada,